Evidence & Research Status
The SURMOUNT-MMO trial represents a shift in how researchers evaluate GLP-1 compounds. Rather than measuring weight loss or glycemic control as primary outcomes, this ongoing tirzepatide trial tracks…
Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.
The SURMOUNT-MMO trial represents a shift in how researchers evaluate GLP-1 compounds. Rather than measuring weight loss or glycemic control as primary outcomes, this ongoing tirzepatide trial tracks all-cause mortality and major cardiovascular events directly in adults with obesity but without diabetes.
Key Takeaways
- SURMOUNT-MMO is notable for using mortality as an endpoint rather than just weight loss, a first for this drug class.
- Trial population and design context help explain why this result matters more broadly.
- Findings are placed alongside retatrutide’s broader Phase 3 program for context.
- Regulatory momentum is building, though full approval implications are still developing.
Why a Mortality Endpoint Changes the Conversation
Most GLP-1 trial programs to date have used weight loss percentage, HbA1c, or other surrogate markers as their primary endpoints. SURMOUNT-MMO is designed differently: its primary endpoint is all-cause mortality and major adverse cardiovascular events (MACE), making it one of the first GLP-1 trials to make longevity itself — not a proxy for it — the central outcome measure researchers are watching.
Trial Population and Design
Primary Endpoint
The trial is tracking all-cause mortality alongside major cardiovascular events such as heart attack and stroke, evaluated over an extended follow-up period consistent with long-horizon cardiovascular outcome trials.
Population Criteria
Enrollment is limited to adults with obesity who do not have type 2 diabetes, a population selection that isolates the effect of tirzepatide on mortality and cardiovascular risk from the confounding effects of pre-existing diabetes management.
Context: How Retatrutide’s Phase 3 Program Compares
SURMOUNT-MMO sits alongside a busy 2026 readout calendar for competing GLP-1-class compounds. Retatrutide, the triple GIP/GLP-1/glucagon receptor agonist covered in our , has posted several Phase 3 readouts of its own in 2026, though none yet with a mortality endpoint.
| Trial | Compound | Population | Primary Endpoint | Status |
|---|---|---|---|---|
| SURMOUNT-MMO | Tirzepatide | Obesity, non-diabetic | All-cause mortality + MACE | Ongoing |
| TRIUMPH-1 | Retatrutide | General obesity (n=2,339) | % weight loss | Complete (May 2026) |
| TRIUMPH-4 | Retatrutide | Knee osteoarthritis population | % weight loss | Complete (Dec 2025) |
| TRANSCEND-T2D-1 | Retatrutide | Type 2 diabetes (n=537) | HbA1c change + % weight loss | Complete (June 2026) |
In head-to-head obesity-population comparisons, retatrutide has posted larger average weight-loss figures (28.3–28.7%) than tirzepatide (about 22.5%) or semaglutide (about 14.9%), per reporting in The Pharmaceutical Journal. But weight-loss magnitude and mortality benefit are not the same measurement, which is precisely why a dedicated mortality-endpoint trial like SURMOUNT-MMO matters for the research record.
Regulatory and Research Momentum
Retatrutide’s developer is expected to submit an NDA in Q4 2026, according to Clinical Trials Arena, which also reported that 11.3% of the high-dose retatrutide cohort discontinued treatment due to adverse events, versus 4.9% in the placebo group. That safety signal is part of the broader risk-benefit picture researchers will need to weigh as mortality-focused data, like that expected from SURMOUNT-MMO, becomes available across the GLP-1 class.
Open Questions for Researchers
- Will retatrutide or other multi-receptor agonists receive a parallel mortality-outcome trial design?
- How should researchers weigh higher adverse-event discontinuation rates against a potential mortality benefit signal?
- Does the shift toward hard outcome endpoints reflect the field increasingly treating GLP-1 compounds as longevity-relevant research subjects rather than purely metabolic ones?
- What confounding factors — lifestyle change, monitoring frequency, population selection — complicate interpretation of mortality data from trials like SURMOUNT-MMO?
All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.
📚 Part of our GLP-1 & Metabolic Research Guide research guide.
Tirzepatide — Research-Grade, Research Use Only